Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gentbrugge – page 36

1 787 clinical trials in Gentbrugge, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gentbrugge at a glance
1 787
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 787 trials in Gentbrugge

Open in trial search

Study on the Safety and Effectiveness of Vibegron for Children Aged 2 to 17 with Neurogenic Bladder Overactivity Using Clean Intermittent Catheterization

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Vibegron
  • Sponsor:Sumitomo Pharma America Inc.

Thermal burn

Recruiting

Study on the Effectiveness of EHSG-KF Skin Graft for Patients with Deep Partial and Full-Thickness Burns

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bilayer Engineered Collagen Hydrogel-Based Skin Graft Composed Of Autologous Keratinocytes And Fibroblasts
  • Sponsor:Cutiss AG

Study of GBT021601 for Adults and Children with Sickle Cell Disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Osivelotor
  • Sponsor:Global Blood Therapeutics Inc.

Study of Efgartigimod PH20 SC for Children Aged 2 to 17 with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Colitis ulcerative+1

Recruiting

Study on Long-term Safety of Vedolizumab and Prednisone in Children with Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Prednisone
  • Sponsor:Takeda Development Center Americas Inc.

Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Crohn's disease

Recruiting

Study of Mirikizumab for Children with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Embolism venous

Recruiting

Study on Venous Thromboembolism Prevention with Enoxaparin Sodium and Drug Combination for Patients Undergoing Total Hip or Knee Replacement

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Ovarian cancer+2

Recruiting

Study on the Safety and Tolerability of TUB-040 for Patients with Platinum-Resistant Ovarian Cancer or Relapsed/Refractory Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:TUB-040
  • Sponsor:Gilead Sciences Inc.

Study of tazemetostat combined with lenalidomide and rituximab in adult patients with relapsed or refractory follicular lymphoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Epizyme Inc.

Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Crisantaspase
  • Sponsor:Pfizer Inc.

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Guselkumab for Children with Moderate to Severe Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Gentbrugge

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) medication management in primary care settings. This research examines optimal strategies for reducing long-term PPI use in patients without clear medical necessity.

  • Functional Dyspepsia
  • Gastroesophageal Reflux
  • Chronic Heartburn Management

The study compares various deprescribing approaches, including on-demand PPI use and alternative treatments with alginate formulations, aiming to establish more effective medication management protocols for patients with chronic digestive conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.